The target site of the novel fungicide quinofumelin, Pyricularia oryzae class II dihydroorotate dehydrogenase. [PDF]
J Pestic Sci, 2022 Higashimura N +5 more
europepmc +1 more source
Dynamic In Vitro PK/PD Infection Models for the Development and Optimisation of Antimicrobial Regimens: A Narrative Review. [PDF]
Antibiotics (Basel)Wale YM, Roberts JA, Sime FB.
europepmc +1 more source
The Four Critical Priority Fungi According to the World Health Organization and the Hope for New Therapies: A Focus on Cell Wall Antifungal Targets. [PDF]
J Fungi (Basel)Marena GD +6 more
europepmc +1 more source
Antifungal Resistance and the Role of New Therapeutic Agents. [PDF]
Curr Infect Dis Rep, 2022 Logan A, Wolfe A, Williamson JC.
europepmc +1 more source
Antifungal Development and the Urgency of Minimizing the Impact of Fungal Diseases on Public Health. [PDF]
ACS Bio Med Chem Au, 2023 de Oliveira HC +2 more
europepmc +1 more source
Anti-<i>Aspergillus</i> activities of olorofim at sub-MIC levels during early-stage growth. [PDF]
Microbiol SpectrKühbacher A +3 more
europepmc +1 more source
Antifungal and fungicide susceptibility of clinical, animal, and environmental Fusarium and Neocosmospora species from Colombia: a one-health approach. [PDF]
Sci RepSaenz V +3 more
europepmc +1 more source
Molecular Mechanism Underlying Resistance Variation to the Novel Agrochemical Quinofumelin in Fusarium graminearum. [PDF]
Mol Plant PatholYin X +8 more
europepmc +1 more source
New and Investigational Treatment Options for Dermatomycosis in the Era of Antifungal Resistance. [PDF]
J Fungi (Basel)Gupta AK, Liddy A, Wang T.
europepmc +1 more source
A case of Lomentospora prolificans endophthalmitis treated with the novel antifungal agent Olorofim. [PDF]
J Ophthalmic Inflamm InfectDong M, Pearce F, Singh N, Lin ML.
europepmc +1 more source